Protara Therapeutics, Inc. reported results
SEC 8-KRead source ↗
Protara Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 2 selling0 purchases and 3 sales by directors and officers, last 12 monthsInsider trades
- Funds76 adding, 45 cuttingOf 29 active managers that changed their stake, 22 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 15% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Protara Therapeutics, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
- Volatile shares. Over the past year the shares showed annualised volatility of 74% and a beta of 1.1 against the S&P 500.
- Heavily shorted. 10.5% of the shares available to trade are sold short (3.6 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
Latest results
- Earnings per share
- -$0.36 against an average estimate of -$0.31: missed by 14.6%
- Share reaction
- -5.4% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
- Next report
- November 10, 2026; average EPS estimate -$0.36
Price chart
- 1 day-2.8%
- 1 week+2.6%
- 1 month-10.7%
- This year-54.8%
- 1 year-53.5%
- 5 years-65.8%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 11, 2026
- Next results (est.)
- November 9, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
No model value for Protara Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 10, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.36 (range −$0.38 to −$0.34) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.39 | −4% | — | 0% |
| Next | −$1.69 | −21% | $1m | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +0.4% on 90 days ago. In the last 30 days, 0 analysts raised Protara Therapeutics, Inc.'s forecast and 5 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$1.39 | −$1.64 |
| 60 days ago | −$1.39 | −$1.69 |
| 30 days ago | −$1.39 | −$1.69 |
| 7 days ago | −$1.39 | −$1.69 |
| Now | −$1.39 | −$1.69 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.31 | −$0.36 | −14.6% |
| Mar 2026 | −$0.37 | −$0.31 | +15.6% |
| Dec 2025 | −$0.31 | −$0.38 | −21.8% |
| Sept 2025 | −$0.39 | −$0.31 | +19.5% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 10.5% of tradable shares
- Days to cover
- 3.63 at average volume
- Short interest, 1 month
- +38% to October 15, 2026
- Held by institutions
- 78% of shares
- Held by insiders
- 2.3% of shares
- Employees
- 46 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| TARA | −72% | −60% | −30% | +182% | +1% | −55% |
| Industry peers (median) | −35% | −56% | −17% | −29% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| TARA | 17% | 42% | 50% | 50% | 50% | 27% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| TARA | −75% | −65% | −71% | −67% | −55% | −69% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 100% from November 30, 2015 to November 22, 2023. Getting back needed a 56576% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $2.32 – $7.56
- From 52-week high
- −68.1%
- vs 50-day average
- −23.7%
- vs 200-day average
- −47.0%
- Volatility (1 year)
- 74%
- Beta vs S&P 500
- 1.05
Share price after results
- Next day
- 5 up, 7 down typical move ±7.0%
- After a week
- 5 up, 7 down typical move ±9.3%
- After a month
- 4 up, 8 down typical move ±24.3%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 11, 2026 | −5.4% | −0.1% | −3.2% | −7.8% |
| May 13, 2026 | +2.9% | +1.4% | −7.6% | −24.3% |
| March 10, 2026 | −2.6% | −0.3% | −5.2% | −7.7% |
| November 10, 2025 | +24.9% | +1.8% | +29.8% | +33.8% |
| August 11, 2025 | −1.9% | +0.9% | +2.9% | −0.6% |
| May 8, 2025 | −3.3% | +0.6% | −7.2% | −2.4% |
| March 5, 2025 | +16.7% | −0.7% | +21.1% | +28.7% |
| November 12, 2024 | +4.3% | −0.3% | −10.1% | +142.2% |
| August 6, 2024 | −8.2% | +0.2% | −7.7% | −8.2% |
| May 2, 2024 | −0.7% | +2.2% | +1.7% | −4.4% |
| March 13, 2024 | 0.0% | −0.4% | +12.9% | −16.0% |
| November 3, 2023 | +13.2% | +1.1% | −1.7% | +15.7% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $176M
- Institutions reporting
- 120
- Shares held vs prior quarter
- ▲ 1.3%
- Positions opened / closed
- 25 / 17
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Jupiter Topco LLC | $17.9M | 4.7M | 10.2% | — |
| Blackrock, Inc. | $14M | 3.7M | 7.9% | ▲ 7.9% |
| Millennium Management LLC | $11.8M | 3.1M | 6.7% | ▲ 9.5% |
| Velan Capital Investment Management LP | $10.9M | 2.8M | 6.2% | ▲ 0.4% |
| Vanguard Capital Management LLC | $8.8M | 2.3M | 5.0% | ▲ 8.5% |
| Blackstone Inc. | $8.7M | 2.3M | 4.9% | 0.0% |
| Orbimed Advisors LLC | $8.5M | 2.2M | 4.8% | New |
| Sio Capital Management, LLC | $7.3M | 1.9M | 4.2% | ▼ 2.4% |
| Acorn Capital Advisors, LLC | $6.7M | 1.8M | 3.8% | 0.0% |
| Integral Health Asset Management, LLC | $5.7M | 1.5M | 3.3% | ▼ 14.3% |
| 5Am Venture Management, LLC | $5.2M | 1.4M | 3.0% | 0.0% |
| Geode Capital Management, LLC | $5.1M | 1.3M | 2.9% | ▲ 12.7% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Protara Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $1M 3 trades by 2 insiders · 12% under pre-set plans
Net ▼ $1M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Shefferman Jesse CEO and President | June 29, 2026 | Sell | 215,687 | $4.09 | $882,160 |
| Zummo Jacqueline Chief R&D Officer | April 8, 2026 | Sell pre-set plan | 1,134 | $5.40 | $6,124 |
| Zummo Jacqueline Chief R&D Officer | April 1, 2026 | Sell pre-set plan | 22,598 | $5.26 | $118,865 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced
- August 11, 2026
- May 13, 2026
- March 10, 2026
- November 10, 2025
- August 11, 2025
- May 8, 2025
Recent SEC filings
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- S-3 REGISTRATION STATEMENT
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Protara Therapeutics, Inc. in brief
- What does Protara Therapeutics, Inc. do?
- Protara Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Protara Therapeutics, Inc.'s stock ticker?
- Protara Therapeutics, Inc. trades under the ticker TARA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Protara Therapeutics, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Jupiter Topco LLC, Blackrock, Inc. and Millennium Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Protara Therapeutics, Inc. stock?
- Over the last 12 months, Protara Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 3 sales on Form 4. The insider trading page charts every trade.
- When is Protara Therapeutics, Inc.'s next earnings date?
- Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Protara Therapeutics, Inc. announces its own schedule.
Follow research on Protara Therapeutics, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.